Hansa Biopharma: Activates the European confirmation study for Idefirix - Redeye

The news is welcome as the 50-patient European PAES study expands the European reference clinics and the study is also a requirement to advance the conditional European Idefirix approval to unconditional approval.

Länk till analysen i sin helhet: https://www.redeye.se/research/848377/hansa-biopharma-activates-the-european-confirmation-study-for-idefirix?utm_source=finwire&utm_medium=RSS